Stay updated on Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial

Sign up to get notified when there's something new on the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T13:49:50.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The webpage has been updated to include new information about a Phase II study on Nivolumab for recurrent IDH-mutated high-grade gliomas, with the addition of collaborators and a revision number. Significant content regarding immune checkpoint blockade therapies has been removed.
    Difference
    47%
    Check dated 2025-04-16T01:47:10.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-08T20:28:31.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-01T15:29:57.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    0.9%
    Check dated 2025-02-24T18:28:22.000Z thumbnail image
  8. Check
    87 days ago
    Change Detected
    Summary
    The webpage now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    0.9%
    Check dated 2025-02-10T09:19:13.000Z thumbnail image

Stay in the know with updates to Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab for Recurrent IDH-Mutated Gliomas Clinical Trial page.